Home › Funds › MPM BioImpact LLC › TARS
MPM BioImpact LLC position in TARS
TARSUS PHARMACEUTICALS INC · Health Care
MPM BioImpact LLC reported holding 322,007 shares of TARS (TARSUS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$20.3M, representing 1.24% of its reported portfolio and ranking #31 among its reported holdings. MPM BioImpact LLC has disclosed TARS holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's TARS position evolved
MPM BioImpact LLC first disclosed a stake in TARS in Q2 2025 at 341,496 shares (US$13.8M). The position peaked in Q4 2025 at 328,869 shares, worth US$26.9M. Across 5 filings, MPM BioImpact LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 322,007 shares valued at US$20.3M — a reduction of -7,743 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 341.50K | $13.83M | New |
| Q3 2025 | 341.50K | $20.30M | Hold |
| Q4 2025 | 328.87K | $26.93M | Reduce |
| Q1 2026 | 329.75K | $23.13M | Hold |
| Q2 2026 | 322.01K | $20.27M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TARS and 13F data
TARS (TARSUS PHARMACEUTICALS INC) is a Health Care company. 39 other funds we track also report a position in TARS — the largest reported positions include Deep Track Capital, LP (US$230.8M), RTW INVESTMENTS, LP (US$211.3M), Paradigm Biocapital Advisors LP (US$174.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TARS
- Deep Track Capital, LP 3.67M sh · $230.79M · Q2 2026
- RTW INVESTMENTS, LP 3.36M sh · $211.29M · Q2 2026
- Paradigm Biocapital Advisors LP 2.78M sh · $174.70M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.57M sh · $98.71M · Q2 2026
- Vestal Point Capital, LP 1.05M sh · $66.09M · Q2 2026
- Frazier Life Sciences Management, L.P. 728.64K sh · $45.86M · Q2 2026
- Tri Locum Partners LP 328.34K sh · $20.67M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held TARS?
MPM BioImpact LLC has disclosed TARS holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is MPM BioImpact LLC's current position in TARS?
As of Q2 2026, MPM BioImpact LLC holds 322.01K shares of TARS (TARSUS PHARMACEUTICALS INC), valued at $20.27M, representing 1.24% of its reported portfolio and ranking #31.
Has MPM BioImpact LLC been buying or selling TARS?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC reduced its position in TARS. The position peaked in Q4 2025 at 328.87K shares.
Which other funds hold TARS?
Other major institutional holders of TARS include Deep Track Capital, LP, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.